knowledge -WSS

knowledge

author：leisure time 2025-09-27 13:05:22 - browse：56278

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Albert Bourla of Pfizer: worst biopharma CEO of 2023

hotspot

WSS

Carvykti CAR

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Winners, losers from Medicare’s list of drugs subject to price talks

Prime Medicine, Myeloid Therapeutics clash over genome

FDA panel gives mixed vote on blood pressure devices

Why health care costs have stayed mostly flat since 2010

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Cancer drug shortages should be causing more outrage

As pharma fights Medicare drug negotiation, hospitals, docs silent

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare explains how it will choose drugs for negotiation

Anesthesiologist group: stop taking Ozempic before surgery

David Ricks of Eli Lilly: best biopharma CEO of 2023

Guidelines to prevent youth baseball injuries need more muscle

Hospitals owned by private equity see complications spike 25%

New air purifier tech could be key to improving indoor air quality

Bristol Myers buys into radiopharmaceuticals with RayzeBio

hotspot

Keeping primary care docs in field isn't impossible, says AAFP CEO

Violet CEO on training clinicians to promote more inclusive care

Appeals court upholds limits to abortion pill

SEC charges former device maker CEO with $41 million fraud

Medicare explains how it will choose drugs for negotiation

Drug firms test therapies to halt Alzheimer’s before symptoms arise

hotspot

hotspot

entertainment

Wikipedia